Company intelligence / Profile preview

NeurGear

New York City*, New York, United Statessa.linkedin.com ↗

Ownership: Private
Employees: ~9
Development stage: Preclinical

Overview

Initial testing of ZenBud shows promising results in promoting relaxation and well-being, reportedly outperforming traditional vagus nerve stimulators. A pre-post intervention clinical trial for anxiety and related symptoms using the ZenBud device began in August 2024; results are pending but initial user feedback indicates deep tranquility and improved quality of life.

Therapeutic areas: Psychiatry
Modalities: DeviceNon-pharmacological therapy (ultrasound-based neurostimulation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ZenBud

Pre-clinical

Indications: Anxiety, Depression, Post-traumatic stress disorder, Stress

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on NeurGear.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeurGear.

Explore the full profile